222 related articles for article (PubMed ID: 31028363)
21. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
22. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
[TBL] [Abstract][Full Text] [Related]
24. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
25. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
26. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
[TBL] [Abstract][Full Text] [Related]
27. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
28. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.
Cowan ML; Springer S; Nguyen D; Taheri D; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; Del Carmen Rodriguez Pena M; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Kinzler K; Bivalacqua T; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2016 Jul; 53():8-13. PubMed ID: 26980028
[TBL] [Abstract][Full Text] [Related]
29. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
Isharwal S; Audenet F; Drill E; Pietzak EJ; Iyer G; Ostrovnaya I; Cha E; Donahue T; Arcila M; Jayakumaran G; Berger MF; Rosenberg JE; Bajorin DF; Coleman J; Dalbagni G; Reuter VE; Bochner BH; Solit DB; Al-Ahmadie HA
Eur Urol Focus; 2019 Mar; 5(2):201-204. PubMed ID: 28802642
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays.
Pritchard JJG; Hamilton G; Hurst CD; Fraser S; Orange C; Knowles MA; Jones RJ; Leung HY; Iwata T
Urol Oncol; 2020 Sep; 38(9):737.e1-737.e10. PubMed ID: 32532529
[TBL] [Abstract][Full Text] [Related]
32. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
33. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
[TBL] [Abstract][Full Text] [Related]
34.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
35. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
36. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
[No Abstract] [Full Text] [Related]
37. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.
Al-Kashwan TA; Houshmand M; Al-Janabi A; Melconian AK; Al-Abbasi D; Al-Musawi MN; Rostami M; Yasseen AA
BMC Res Notes; 2012 Aug; 5():466. PubMed ID: 22929185
[TBL] [Abstract][Full Text] [Related]
38. HRAS mutations are frequent in inverted urothelial neoplasms.
McDaniel AS; Zhai Y; Cho KR; Dhanasekaran SM; Montgomery JS; Palapattu G; Siddiqui J; Morgan T; Alva A; Weizer A; Lee CT; Chinnaiyan AM; Quist MJ; Grasso CS; Tomlins SA; Mehra R
Hum Pathol; 2014 Sep; 45(9):1957-65. PubMed ID: 25097040
[TBL] [Abstract][Full Text] [Related]
39. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]